Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Jefferies trims ratings on Hays, Ashtead

(Sharecast News) - Jefferies has cut its recommendations on Hays and Ashtead Group, following a review of Europe's business and employment services sector.

In a note published on Thursday, the investment bank said: "We continue to believe earnings momentum and market positioning will remain a key driver of relative performance for the second half of 2025."

It upgraded Denmark's ISS to 'buy' from 'hold', noting that improving commercial momentum could drive organic growth up to 5-6% in 2026, while the outlook for free cashflow generation remained "strong".

Zurich-based Adecco was upgraded to 'hold' from 'underperform', "reflecting our more constructive view on the temp volumes following the improving momentum over the last few months, together with business development and cost initiatives".

In contrast, Ashtead was downgraded to 'hold' from 'buy'. "Ashtead's shares have rallied strongly and re-rated on improving US construction outlook sentiment, but near-term earnings momentum we think remains muted," Jefferies said.

Hays was also cut to 'hold' from a previous 'buy' rating. Jefferies argued: "We expect earnings momentum to remain negative on the back of continued headwinds on perm and as we anticipate further downgrades."

Overall, Jefferies flagged Bureau Veritas, Intertek, Elis, Compass, Experian and ISS as its preferred stocks in the sector.

Its least preferred are Bunzl, Securitas, Sodexo, Eurofins and Mitie.

As at 1215 BST, London-listed Hays and Ashtead were down 2% at 57.75p and off 1% at 5,360.19p respectively.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.